Hepaclear Infusion contains L-Ornithine L-Aspartate (5 gm) as its active ingredient, indicated primarily for the management of hepatic encephalopathy and related liver dysfunctions. This compound acts by facilitating the detoxification of ammonia, a neurotoxin that accumulates in patients with compromised liver function. L-Ornithine L-Aspartate enhances the urea cycle and glutamine synthesis in the liver and skeletal muscles, thereby reducing elevated blood ammonia levels and improving neurological symptoms associated with hepatic encephalopathy. Hepaclear Infusion is administered intravenously, allowing for rapid bioavailability and effective plasma concentration in acute and chronic liver conditions. It is particularly beneficial in patients with cirrhosis, acute liver failure, or those undergoing procedures that may precipitate encephalopathy. The infusion should be used under strict medical supervision, with dosage tailored according to the severity of the condition and patient response. Common precautions include monitoring for electrolyte imbalances and renal function during prolonged therapy. Hepaclear Infusion is contraindicated in patients with hypersensitivity to L-Ornithine L-Aspartate or any component of the formulation. Its use should be carefully considered in pregnant or lactating women due to limited safety data. Overall, Hepaclear Infusion represents an effective therapeutic option for managing hyperammonemia and improving quality of life in patients with hepatic insufficiency.